Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21660
Title: Management of patients with EPP related progressive liver disease.
Authors: Arladan, Zaid S;Chandran, S;Vasudevan, A;Angus, Peter W;Grigg, Andrew P;He, Simon;Macdonald, G A;Strasser, S I;Tate, C J;Kennedy, G A;Testro, Adam G;Gow, Paul J
Affiliation: Department of Gastroenterology, Eastern Health, Melbourne, Australia
Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Australia
Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia
Melbourne University, Melbourne, Australia
AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia
University of Sydney, Sydney, Australia
Department of Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia
University of Queensland, Brisbane, Australia
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 30-Aug-2019
EDate: 2019-08-30
Citation: Liver transplantation 2019; online first: 30 August
Abstract: Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX) which can lead to progressive liver disease characterized by recurrent EPP crisis and end stage liver disease. We utilized the Australian Transplant Registry to identify five patients referred for liver transplantation between 2008 and 2017. Four patients had EPP secondary to ferrochelatase (FECH) deficiency and one had X-Linked EPP (XLP). No patient had specialist follow-up prior to the diagnosis of progressive liver disease. Three patients underwent orthotopic liver transplant (OLT), while two died while on the transplant waiting list. Parenteral PPIX-lowering therapy was utilized in four patients and was effective in three patients although two of these had rebound porphyria and worsening liver function following decreasing the intensity of therapy. Early disease recurrence in the allograft following transplantation occurred in two patients requiring red cell exchange (RCE) to successfully attain and maintain low PPIX levels, but RCE was associated with hemosiderosis in one case. Allogeneic stem cell transplantation (AlloSCT) was performed in two patients. One failed engraftment twice while the second rejected their first graft but achieved full donor chimerism with a second graft and increased immunosuppression. Conclusion: Our observations suggest that progressive liver disease needs parenteral PPIX-lowering treatment with the intensity adjusted to achieve a target Erc-PPIX level. Since recurrent EPP liver disease is the rule, AlloSCT should be considered in all patients with adequate immunosuppression to facilitate engraftment. RCE appears effective for recurrent EPP liver disease but is associated with an increased risk of iron overload. This article is protected by copyright. All rights reserved.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21660
DOI: 10.1002/lt.25632
PubMed URL: 31469227
Type: Journal Article
Subjects: XLP
Allogeneic stem cell transplant
Kew words
Liver transplantation
Protoporphyrin IX
Red cell exchange
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.